Related Experiment Videos
Malignant melanoma associates with deficient IFN-induced STAT 1 phosphorylation
Jan Kovarik1, V Boudny, I Kocak
1Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic. kovarik@mou.cz
Abstract:
STAT 1, a member of signal transducers and transcription activators of STAT family proteins, has been implicated as important mediator of IFN signaling. Functional activation of STAT 1 requires tyrosine and serine phosphorylation. Defects in its expression or activation in response to IFNs were observed in numerous pathological conditions including cancer. To further explore cancer-associated impaired STAT 1 response to IFNs, the inducibility of serine (S 727) and tyrosine (Y 701) phosphorylation by IFN-alpha/-gamma was assessed in 21 melanoma cell lines and in 35 primary cultures derived from melanoma patients. STAT 1 levels and inducibility of its activated phospho-forms were detected by Western analysis using specific polyclonal and monoclonal antibodies. All cell lines as well as patient melanoma samples expressed STAT 1 with variable signal intensity. Significant impaired IFN-induced STAT 1 S 727 phosphorylation was observed in both model systems with average of 77% of non-responders recorded in patient melanoma cells and 76% in melanoma cell lines. Failure of PY 701 induction occurred in patient samples (63% after IFN-alpha and 34% after IFN-gamma induction) and to a lesser degree in cell lines (i.e. response absence to IFN-alpha in 5 and to IFN-gamma in 2 melanoma lines). Our study demonstrates STAT 1 functional abnormalities in melanoma cells. On the basis of detailed analyses of patient melanoma cells with respect to the inducibility of STAT 1 phosphorylation by IFNs, four categories of patients could be distinguished: a) activation on both S 727 and Y 701, b) not inducible response, c) activation on Y 701 but not on S 727, d) heterogeneous response. Clinical study is now in progress to establish the significance of in vitro STAT 1 activation for predicting the response to IFN-based therapy and to explore biological consequences in cases responding in vitro to IFN-induced STAT 1 activation on only one of the critical amino acid residues.
Insights
Melanoma cells show impaired STAT 1 activation in response to interferons (IFNs), affecting both serine and tyrosine phosphorylation. This STAT 1 dysfunction is common in melanoma and may impact treatment outcomes.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Signal transducer and activator of transcription 1 (STAT 1) is crucial for interferon (IFN) signaling.
- STAT 1 activation, involving serine and tyrosine phosphorylation, is essential for its function.
- Impaired STAT 1 signaling is linked to various cancers, including melanoma.
Purpose of the Study:
- To investigate impaired STAT 1 response to IFN-alpha and IFN-gamma in melanoma.
- To assess the inducibility of STAT 1 serine (S 727) and tyrosine (Y 701) phosphorylation in melanoma cell lines and patient samples.
- To categorize patient responses based on STAT 1 phosphorylation patterns.
Main Methods:
- Western blot analysis was used to detect STAT 1 levels and phosphorylated forms (p-STAT 1).
- Specific antibodies were employed to quantify STAT 1 phosphorylation at S 727 and Y 701.
- The study analyzed 21 melanoma cell lines and 35 primary melanoma patient cultures.
Main Results:
- Significant impairment in IFN-induced STAT 1 S 727 phosphorylation was observed in 76% of cell lines and 77% of patient samples.
- Failure of Y 701 induction occurred in 63% (IFN-alpha) and 34% (IFN-gamma) of patient samples, and less frequently in cell lines.
- Four distinct categories of STAT 1 phosphorylation response were identified in melanoma patients.
Conclusions:
- Melanoma cells exhibit significant functional abnormalities in STAT 1 activation pathways.
- STAT 1 phosphorylation defects are prevalent in melanoma, suggesting a role in disease progression.
- Further clinical studies will correlate in vitro STAT 1 activation with IFN-based therapy response and outcomes.